Breast cancer can be classified into several molecular subtypes (luminal A, luminal B, HER2-positive and triple-negative), which differ in their prognosis, as well as into different systemic therapy options (e.g., chemotherapy, endocrine therapy, anti-HER2 therapy) [4]. This evidence concerns the gene ERBB2 and breast carcinoma.